Boston Consulting Group announced it has entered a strategic collaboration with Merck, known as MSD outside of the United States and Canada. The collaboration will leverage artificial intelligence and generative artificial intelligence (AI and GenAI) to potentially enable the discovery and assessment of novel drug targets.